The TruSeq Amplicon Cancer Panel has been discontinued. The AmpliSeq for Illumina Focus Panel is the recommended replacement.

TruSeq Amplicon - Cancer Panel (discontinued)

This highly multiplexed targeted resequencing assay enables researchers to detect somatic mutations in a variety of cancer-related genes.Read More...

The TruSeq Amplicon - Cancer Panel enables highly sensitive mutation detection studies of important cancer-related genes, including BRAF, KRAS, and EGFR. Mutations in these genes are linked to many cancers, including melanoma, colorectal, ovarian, and lung cancer.

Product Highlights

This panel provides:

  • A streamlined workflow including an integrated quality control assay for formalin-fixed, paraffin-embedded (FFPE) DNA
  • Simple sample normalization
  • Automated cluster generation and paired-end sequencing
  • On-instrument data analysis

The unique ability of this assay to screen precious FFPE samples for these important variants enables researchers to unlock a wealth of genomic information for many tumor types.

Genes in This Panel

See which cancer-related genes are represented in this panel.

View Gene List

See All Illumina Cancer Research Panels

Frequently Purchased Together

Specifications

Method-Specific Workflow Example

 

Supporting Data and Figures

TruSeq Amplicon - Cancer Panel Workflow Overview
TruSeq Amplicon Cancer Panel workflow image

This comprehensive assay enables researchers to examine a wide variety of relevant cancer mutations, even in challenging FFPE samples. Labs can go from genomic DNA to fully analyzed data in less than 2 days with the MiSeq System.

 
TruSeq Amplicon - Cancer Panel Gene List
ABL1 EGFR GNAS MLH1 RET
AKT1 ERBB2 HNF1A MPL SMAD4
ALK ERBB4 HRAS NOTCH1 SMARCB1
APC FBXW7 IDH1 NPM1 SMO
ATM FGFR1 JAK2 NRAS SRC
BRAF FGFR2 JAK3 PDGFRA STK11
CDH1 FGFR3 KDR PIK3CA TP53
CDKN2A FLT3 KIT PTEN VHL
CSF1R GNA11 KRAS PTPN11  
CTNNB1 GNAQ MET RB1  

Related Products

TruSight Tumor 15

Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.


TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.


TruSight RNA Pan-Cancer

Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.